Jennison Associates’s Tandem Diabetes Care TNDM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $35.2M | Buy |
2,331,429
+672,981
| +41% | +$11.8M | 0.02% | 276 |
|
|
2026
Q1 | $31.8M | Sell |
1,658,448
-362,928
| -18% | -$7.89M | 0.02% | 280 |
|
|
2025
Q4 | $44.4M | Buy |
2,021,376
+601,260
| +42% | +$10.9M | 0.03% | 228 |
|
|
2025
Q3 | $17.2M | Sell |
1,420,116
-238,826
| -14% | -$3.23M | 0.01% | 338 |
|
|
2025
Q2 | $30.9M | Buy |
1,658,942
+181,834
| +12% | +$3.6M | 0.02% | 279 |
|
|
2025
Q1 | $28.3M | Buy |
1,477,108
+10,753
| +0.7% | +$315K | 0.02% | 287 |
|
|
2024
Q4 | $52.8M | Sell |
1,466,355
-315,648
| -18% | -$10.7M | 0.03% | 221 |
|
|
2024
Q3 | $75.6M | Sell |
1,782,003
-187,623
| -10% | -$7.96M | 0.05% | 161 |
|
|
2024
Q2 | $79.4M | Sell |
1,969,626
-586,498
| -23% | -$24.5M | 0.05% | 148 |
|
|
2024
Q1 | $90.5M | Buy |
2,556,124
+1,265,534
| +98% | +$33.9M | 0.06% | 129 |
|
|
2023
Q4 | $38.2M | Buy |
1,290,590
+167,675
| +15% | +$3.48M | 0.03% | 239 |
|
|
2023
Q3 | $23.3M | Buy |
1,122,915
+804,488
| +253% | +$22.1M | 0.02% | 294 |
|
|
2023
Q2 | $7.81M | Buy |
+318,427
| New | +$10.2M | 0.01% | 395 |
|
|
2022
Q1 | – | Sell |
-277,581
| Closed | -$41.8M | – | 705 |
|
|
2021
Q4 | $41.8M | Sell |
277,581
-283,302
| -51% | -$38.2M | 0.03% | 255 |
|
|
2021
Q3 | $67M | Buy |
560,883
+27,914
| +5% | +$3.08M | 0.04% | 168 |
|
|
2021
Q2 | $51.9M | Buy |
532,969
+16,035
| +3% | +$1.43M | 0.03% | 217 |
|
|
2021
Q1 | $45.6M | Sell |
516,934
-29,642
| -5% | -$2.75M | 0.03% | 231 |
|
|
2020
Q4 | $52.3M | Sell |
546,576
-17,891
| -3% | -$1.84M | 0.04% | 200 |
|
|
2020
Q3 | $64.1M | Buy |
564,467
+104,601
| +23% | +$11M | 0.05% | 144 |
|
|
2020
Q2 | $45.5M | Sell |
459,866
-177,271
| -28% | -$14.1M | 0.04% | 177 |
|
|
2020
Q1 | $41M | Buy |
637,137
+132,532
| +26% | +$9.29M | 0.05% | 165 |
|
|
2019
Q4 | $30.1M | Buy |
+504,605
| New | +$31.1M | 0.03% | 256 |
|
|
2016
Q3 | – | Sell |
-3,703
| Closed | -$279K | – | 684 |
|
|
2016
Q2 | $279K | Buy |
3,703
+614
| +20% | +$49.4K | ﹤0.01% | 623 |
|
|
2016
Q1 | $269K | Buy |
3,089
+102
| +3% | +$8.93K | ﹤0.01% | 602 |
|
|
2015
Q4 | $353K | Buy |
+2,987
| New | +$296K | ﹤0.01% | 641 |
|
|
2015
Q1 | – | Sell |
-69,997
| Closed | -$8.89M | – | 749 |
|
|
2014
Q4 | $8.89M | Sell |
69,997
-57,207
| -45% | -$7.93M | 0.01% | 490 |
|
|
2014
Q3 | $17.1M | Buy |
127,204
+5,268
| +4% | +$738K | 0.02% | 447 |
|
|
2014
Q2 | $19.8M | Buy |
121,936
+17,689
| +17% | +$3.01M | 0.02% | 431 |
|
|
2014
Q1 | $23M | Buy |
104,247
+9,805
| +10% | +$2.5M | 0.02% | 430 |
|
|
2013
Q4 | $24.3M | Buy |
+94,442
| New | +$21.6M | 0.02% | 426 |
|
Other funds holding TNDM
SC
FLAM
GKIM
PIM
FGP
Jennison Associates's TNDM Position: Q2 2026 in Review
Jennison Associates increased its Tandem Diabetes Care (TNDM) stake by 41% in Q2 2026, buying an estimated $11.8M and bringing the position to 2,331,429 shares worth $35.2M. The position accounts for 0.02% of the portfolio, ranked #276.
Jennison Associates first reported a position in TNDM in Q4 2013 and has held it in 30 quarters since. The position peaked at $90.5M in Q1 2024. 273 funds tracked by Wall St. Rank hold TNDM as of Q2 2026.
- Jennison Associates held 2,331,429 shares of Tandem Diabetes Care worth $35.2M as of Q2 2026.
- Jennison Associates bought 672,981 Tandem Diabetes Care shares in Q2 2026, an estimated $11.8M.
- Tandem Diabetes Care made up 0.02% of Jennison Associates's portfolio in Q2 2026, its #276 holding.
- Jennison Associates first reported a position in Tandem Diabetes Care in Q4 2013 and has held it in 30 quarters since.
- Jennison Associates's Tandem Diabetes Care position peaked at $90.5M in Q1 2024.
- 273 funds tracked by Wall St. Rank held Tandem Diabetes Care as of Q2 2026.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.